Literature DB >> 27286745

An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease.

Barth Wilsey1, Thomas D Marcotte2, Reena Deutsch2, Holly Zhao3, Hannah Prasad3, Amy Phan3.   

Abstract

UNLABELLED: Using 8-hour human laboratory experiments, we evaluated the analgesic efficacy of vaporized cannabis in patients with neuropathic pain related to injury or disease of the spinal cord, most of whom were experiencing pain despite traditional treatment. After obtaining baseline data, 42 participants underwent a standardized procedure for inhaling 4 puffs of vaporized cannabis containing either placebo, 2.9%, or 6.7% delta 9-THC on 3 separate occasions. A second dosing occurred 3 hours later; participants chose to inhale 4 to 8 puffs. This flexible dosing was used to attempt to reduce the placebo effect. Using an 11-point numerical pain intensity rating scale as the primary outcome, a mixed effects linear regression model showed a significant analgesic response for vaporized cannabis. When subjective and psychoactive side effects (eg, good drug effect, feeling high, etc) were added as covariates to the model, the reduction in pain intensity remained significant above and beyond any effect of these measures (all P < .0004). Psychoactive and subjective effects were dose-dependent. Measurement of neuropsychological performance proved challenging because of various disabilities in the population studied. Because the 2 active doses did not significantly differ from each other in terms of analgesic potency, the lower dose appears to offer the best risk-benefit ratio in patients with neuropathic pain associated with injury or disease of the spinal cord. PERSPECTIVE: A crossover, randomized, placebo-controlled human laboratory experiment involving administration of vaporized cannabis was performed in patients with neuropathic pain related to spinal cord injury and disease. This study supports consideration of future research that would include longer duration studies over weeks to months to evaluate the efficacy of medicinal cannabis in patients with central neuropathic pain.
Copyright © 2016 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neuropathic pain; analgesia; cannabis; clinical trial; neuropsychological testing

Mesh:

Substances:

Year:  2016        PMID: 27286745      PMCID: PMC5007175          DOI: 10.1016/j.jpain.2016.05.010

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  104 in total

Review 1.  Medicinal cannabis: rational guidelines for dosing.

Authors:  Gregory T Carter; Patrick Weydt; Muraco Kyashna-Tocha; Donald I Abrams
Journal:  IDrugs       Date:  2004-05

Review 2.  Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review.

Authors:  Jeanette M Tetrault; Kristina Crothers; Brent A Moore; Reena Mehra; John Concato; David A Fiellin
Journal:  Arch Intern Med       Date:  2007-02-12

3.  Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.

Authors:  Michael Iskedjian; Basil Bereza; Allan Gordon; Charles Piwko; Thomas R Einarson
Journal:  Curr Med Res Opin       Date:  2007-01       Impact factor: 2.580

4.  Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale.

Authors:  B S Galer; M P Jensen
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

5.  Modified Ashworth scale reliability for measurement of lower extremity spasticity among patients with SCI.

Authors:  B C Craven; A R Morris
Journal:  Spinal Cord       Date:  2009-09-29       Impact factor: 2.772

Review 6.  Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations.

Authors:  Robert H Dworkin; Dennis C Turk; Sarah Peirce-Sandner; Ralf Baron; Nicholas Bellamy; Laurie B Burke; Amy Chappell; Kevin Chartier; Charles S Cleeland; Ann Costello; Penney Cowan; Rozalina Dimitrova; Susan Ellenberg; John T Farrar; Jacqueline A French; Ian Gilron; Sharon Hertz; Alejandro R Jadad; Gary W Jay; Jarkko Kalliomäki; Nathaniel P Katz; Robert D Kerns; Donald C Manning; Michael P McDermott; Patrick J McGrath; Arvind Narayana; Linda Porter; Steve Quessy; Bob A Rappaport; Christine Rauschkolb; Bryce B Reeve; Thomas Rhodes; Cristina Sampaio; David M Simpson; Joseph W Stauffer; Gerold Stucki; Jeffrey Tobias; Richard E White; James Witter
Journal:  Pain       Date:  2010-03-06       Impact factor: 6.961

7.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

8.  National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity.

Authors:  L N Robins; J E Helzer; J Croughan; K S Ratcliff
Journal:  Arch Gen Psychiatry       Date:  1981-04

9.  Practice effects during repeated administrations of memory tests with and without alternate forms.

Authors:  R H Benedict; D J Zgaljardic
Journal:  J Clin Exp Neuropsychol       Date:  1998-06       Impact factor: 2.475

10.  Clinical use of pregabalin in the management of central neuropathic pain.

Authors:  Nanna B Finnerup; Troels S Jensen
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more
  28 in total

Review 1.  Medical cannabis: aligning use to evidence-based medicine approach.

Authors:  Lihi Bar-Lev Schleider; Ran Abuhasira; Victor Novack
Journal:  Br J Clin Pharmacol       Date:  2018-08-28       Impact factor: 4.335

2.  Should Medical Cannabis Administered by Inhalation Be Allowed for Hospitalized Patients?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2018-06-28

Review 3.  Cannabis for Pain and Headaches: Primer.

Authors:  Philip S Kim; Michael A Fishman
Journal:  Curr Pain Headache Rep       Date:  2017-04

Review 4.  Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective.

Authors:  Ziva D Cooper; Rebecca M Craft
Journal:  Neuropsychopharmacology       Date:  2017-07-17       Impact factor: 7.853

Review 5.  Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies.

Authors:  Ziva D Cooper; Donald I Abrams
Journal:  Am J Drug Alcohol Abuse       Date:  2019-11-05       Impact factor: 3.829

6.  The Management of Cancer Symptoms and Treatment-Induced Side Effects With Cannabis or Cannabinoids.

Authors:  Michelle Sexton; Jose M Garcia; Aminah Jatoi; Carey S Clark; Mark S Wallace
Journal:  J Natl Cancer Inst Monogr       Date:  2021-11-28

Review 7.  Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility: Preclinical and Clinical-Based Evidence.

Authors:  Rishabh Verma; Farazul Hoda; Mawrah Arshad; Asif Iqubal; Ali Nasir Siddiqui; Mohammad Ahmed Khan; Syed Ehtaishamul Haque; Mohd Akhtar; Abul Kalam Najmi
Journal:  Med Cannabis Cannabinoids       Date:  2021-05-21

Review 8.  Medical Cannabis for Neuropathic Pain.

Authors:  Gemayel Lee; Brittany Grovey; Tim Furnish; Mark Wallace
Journal:  Curr Pain Headache Rep       Date:  2018-02-01

Review 9.  Cannabis and Cannabinoids for Chronic Pain.

Authors:  E Alfonso Romero-Sandoval; Ashley L Kolano; P Abigail Alvarado-Vázquez
Journal:  Curr Rheumatol Rep       Date:  2017-10-05       Impact factor: 4.592

Review 10.  Cannabis shenanigans: advocating for the restoration of an effective treatment of pain following spinal cord injury.

Authors:  Daniel E Graves
Journal:  Spinal Cord Ser Cases       Date:  2018-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.